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1 Abbreviations 
ALAT Alanin aminotransferase 
AP Alkaline phosphatase 
BMI Body-mass index 
CALU Calumenin 
CI Confidence interval 
CHF Congestive heart failure 
COPD Chronic obstructive pulmonary disease 
CRP C-reactive protein  
CYP Cytochrome P450 isoenzyme 
eGFR estimated glomerular filtration rate 
EPHX Microsomal epoxide hydrolase 
FPH Foederatio Pharmaceutica Helvetiae 
F Factor 
GGCX -glutamyl carboxylase 
GI gastrointestinal 
INR International normalized ratio 
N Number of cases 
no. Number 
n.s. not significant 
NSAID Nonsteroidal anti-inflammatory Drug 
OA(s) Oral anticoagulant(s) 
OAC Oral anticoagulation 
OR Odds ratio 
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p Probability 
PROC Protein C 
PTT Partial thromboplastin time 
Ref. reference 
SNP(s) Single nucleotide polymorphism(s)  
Tc Thrombocyte 
VKA(s) Vitamin K antagonist(s) 
VKOR Vitamin-K-epoxide-reductase 
VKORC1 Vitamin K reductase complex subunit 1 
WHO World Health Organisation 
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2 Introduction 
Vitamin-K antagonists (VKAs) of the coumarin type are widely-used oral 
anticoagulants (OAs). They have proven to be highly effective antithrombotic drugs 
for the treatment or prevention of deep venous thrombosis, pulmonary embolism, and 
certain forms of ischaemic stroke. [1-3]  
Adverse Effects of OAs 
Beside these well-confirmed beneficial effects, OAs are associated with adverse 
effects, primarily the risk of bleeding. Anticoagulant-related bleeding is common and 
often serious. Indeed, OAs are the leading class of drug-associated adverse effects 
that result in hospitalization. [4-5] Every year, 10-17% of patients on anticoagulant 
therapy experience bleeding complications, and the incidence rate of serious 
bleeding (i.e. requiring hospitalization, blood transfusion and/or surgery) and fatal 
bleeding is 2-5 and 0.5-1 per 100 patient-years, respectively. [6-11]  
In the United States, more than 30 million patients are treated with OAs and 29,000 
visits caused by bleeding complications are observed each year. [12]  
The anticoagulant warfarin represents the leading cause of lethal adverse drug 
reactions in the United States. [12] Major bleeding most often affects the 
gastrointestinal tract, soft tissues, and the urinary tract. Ansell et al. analysed 3,791 
warfarin-treated patients from the National Registry of Atrial Fibrillation. They found 
that the rate of admissions for bleeding was 5.2 per 100 patient-years. Of these, 
67.3% were gastrointestinal and 15.4% were intracranial hemorrhages; the overall 
30-day mortality of patients admitted with major hemorrhage was 21.6%. [13] 
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Intensity of Anticoagulation 
The international normalized ratio (INR) is used to measure the intensity of oral 
anticoagulation and should be maintained within a small therapeutic range usually 
between 2.0 to 3.0 for a long-term therapy. [14]  
 
Figure 1 shows the conceptual model of the target INR with the best risk-benefit ratio. 
[8, 15-17] 
 
 
 
 
 
 
 
 
  
 Figure 1: Conceptual model for the definition of an optimized range of the target-INR  
 
The optimum range depends on two competing risks: the risk of thromboembolism 
and the risk of bleeding. Both risks vary with patient factors. These patient factors 
can shift one or both risk-curves, which necessitates an individualized definition of 
the optimum target-INR. Factors enhancing the risk of bleeding include advanced 
age, gender, co-morbidity, concurrent medication, interactions with food, lower body 
mass index and others. [7-8, 12, 18-20] 
Risk
Risk of bleeding
INR
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On the other hand, the risk of thromboembolism is enhanced in certain procoagulant 
states or in patients with certain mechanical valvular prostheses, where a higher  
intensity of OAC therapy may be required. [20] Finally, co-morbidity and medical 
interventions may both increase the risk of thrombosis and bleeding. 
 
Nevertheless, it has always to be kept in mind that the INR is only a surrogate of the 
true intensity of anticoagulation. Especially during the first days of anticoagulation the 
INR only partly reflects the degree of protection from thromboembolism or the risk of 
bleeding because of the clotting factors’ different half-lives. [16] 
 
Even more importantly during the initial phase of treatment, bleeding complications or 
recurrent thrombosis caused by overanticoagulation or underanticoagulation can 
occur due to the large variability in the dose-response relationship and the narrow 
therapeutic range of coumarins. [18] These complications can lead to extended 
hospitalization. 
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Coumarin Derivatives 
The coumarins most frequently used in humans are warfarin, acenocoumarol and 
phenprocoumon. Warfarin is the coumarin of first choice in the United States of 
America, the United Kingdom and many other countries around the world; 
acenocoumarol and phenprocoumon are frequently used in many European 
countries. In Switzerland, phenprocoumon is the drug of choice for long-term 
treatment and prevention of thromboembolic events.  
The three coumarin derivatives mentioned above mainly differ in their half-life (cf. 
table 1). [21-22] 
 
Table 1: Pharmacokinetic parameters of vitamin K antagonists [23-24] 
Parameter Phenprocoumon Acenocoumarol Warfarin 
Volume of distribution [L/kg] 0.11 – 0.14  0.22 – 0.52 0.08 – 0.12 
Protein binding [%] > 99 > 98 > 99 
Plasma concentration* [mol/L] 1.5 – 15  0.03 – 0.3  1.5 – 8  
Terminal elimination half-life [h] S: 110 – 172 
R: 110 – 156  
S: 1.8 
R: 6.6 
S: 24 – 33  
R: 35 – 58  
Plasma clearance [L/h] S: 0.045 – 0.055  
R: 0.055 – 0.08  
S: 28.5 
R: 1.9 
S: 0.10 – 1.0  
R: 0.07 – 0.35  
Elimination kinetics First-order Biphasic First-order 
* Refers to the total plasma concentration of bound and unbound racemic drug during therapeutic anticoagulation 
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Coumarins - Mechanism of Action 
Coumarins work by decreasing the activation of vitamin-K-dependant clotting factors 
(II, VII, IX and X). Reduced vitamin K is needed for the carboxylation (activation) of 
these clotting factors. Coumarins inhibit vitamin-K-epoxide-reductase (VKOR), which 
recycles oxidized vitamin K (inactive) into reduced vitamin K (active). Vitamin K is 
thus a cofactor for the carboxylation of the vitamin K-dependent coagulation factors. 
These coagulation factors require -carboxylation by vitamin K for their biological 
activity. OAs inhibit vitamin-K-epoxide-reductase, resulting in insufficient generation 
of vitamin K hydroquinone to support full carboxylation and therefore full function of 
the vitamin K-dependent coagulation factors. [24-28] 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 2: vitamin K cycle modified according to Wallin et al. [29] 
 
vitamin K cycle
phenprocoumon Vitamin K 2,3-epoxide
Vitamin K quinone
vitamin K-epoxide-
reductase-complex (VKOR)
vitamin K-epoxide-
reductase-complex (VKOR)
-glutamyl-carboxylase
Protein bounded -carboxylglutamateProtein bounded glutamat
Vitamin K hydroquinone
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This mechanism makes clear why the effect of coumarins is delayed. The latency 
period is 1-3 days because of the prolonged half-life of intact clotting factors. Only 
when the concentration of the clotting factors in the blood drops below a critical level, 
the reduced or missing regeneration in the liver becomes manifest. 
Role of Vitamin K 
Vitamin K is the family name for a number of fat-soluble compounds. They are 
synthesised by plants and bacteria. In plants the only important molecular form is 
phylloquinone (vitamin K1). Bacteria synthesise a family of compounds called 
menaquinones (vitamin K2). The highest concentrations of phylloquinone are found in 
green vegetables. Significant concentrations of menaquinones can be found in 
animal livers and in fermented foods, typically represented by cheese. [30]  
The human intestinal microflora also synthesise large amounts of menaquinones. But 
the question whether the colonic microbiota provide a quantitatively significant source 
of menaquinones that can be absorbed and utilised has still not been satisfactorily 
answered. [26, 30]  
Vitamin K1 has an antidotal effect to vitamin-K antagonists. Schurgers et al. controlled 
vitamin K intake and increased content of dietary vitamin K weekly. The more the 
dose of vitamin K increases, the more the INR values decrease correspondingly. [31]  
When bleeding under OAC occurs, 5 – 10 (as antidot up to 20) milligrams of vitamin 
K1 are given. [32-33] In contrast to the relatively slow onset (several days) of 
anticoagulation in acute inhibition of VKOR by coumarins, gamma carboxylation of 
inactive coagulation factors can be achieved within only a few hours if sufficient  
vitamin K is provided as an antidote even in the presence of high coumarin blood 
levels.  
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The aim of oral anticoagulation therapy is to achieve a balance between the degree 
of inhibition of the VKOR enzyme and the availability of reduced vitamin K that feeds 
into the vitamin K cycle and drives the synthesis of the clotting factors at a reduced 
rate. Ideally, to achieve stable anticoagulation with a constant daily dose of a VKA, 
the daily amounts of vitamin K available at the hepatic site of synthesis of the  
vitamin K-dependent clotting factors need to be kept constant as well. In reality this is 
difficult because the major dietary source, phylloquinone (vitamin K1), is present in 
different foods at very variable concentrations. Lubetsky et al. found in their study a 
range of daily vitamin K consumption of 17-974 g which corresponds to a mean +/- 
SD of 248.3 ± 205 g/day and a median of 179 g/day. [34] Most surveys have 
shown that actual intakes of vitamin K in the USA and European populations vary 
widely between individuals but that the mean intakes are in the range of 60 – 200 
g/day. [35-36] Nevertheless, if dietary excesses are avoided, and given the 
relatively long half-lives of both vitamin K and VKAs, anticoagulation can usually be 
kept in a relatively narrow range in most individuals.  
The best advice therefore is to continue normal dietary patterns and avoid gross daily 
fluctuations in intakes of vitamin K. There is limited quantitative information of dose-
response relationships that are predictive of how changing dietary intakes of 
phylloquinone affect the pharmacodynamic response to OA. Schurgers et al. found 
that the threshold K1 dose causing a statistically significant lowering of the INR was  
150 g/day. [31]  In patients, the most informative study to date suggests that, on 
average, for every 100 g increase in phylloquinone intake in the 4 days before the 
INR is measured the INR will fall by 0.2 units. [37]
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Pharmacokinetics of Phenprocoumon 
Phenprocoumon exists as optical isomers. It is a long-acting agent, with both the R- 
and the S-isomers having elimination half-lives of up to 5.5 days. S-phenprocoumon 
is 1.5-2.5 times more potent than R-phenprocoumon. Therefore, the S-enantiomer is 
predominantly responsible for the anticoagulant effect in phenprocoumon. [16, 24, 
38] 
Because of the long half-life phenprocoumon has the potential to sustain a stable 
anticoagulation. But it also takes more time to reach the steady state than shorter 
acting coumarins. That is why a loading dose of phenprocoumon is essential.  
Otherwise, it would take up to four weeks for an equal dose to reach the steady state. 
 
 
Figure 3: Structure of phenprocoumon [39] 
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Factors Influencing Pharmacokinetics and Pharmacodynamics of Phenprocoumon   
The stability of anticoagulant therapy can be easily disturbed. Environmental factors 
such as drugs, diet, and various disease states can alter the pharmacokinetics of 
phenprocoumon. Drugs like cholestyramine can reduce the anticoagulant effect of 
phenprocoumon by reducing its absorption. The risk of overanticoagulation and 
underanticoagulation in patients taking VKAs is associated with drug – VKAs 
interactions. Some drugs potentiate the anticoagulant effect of phenprocoumon by 
inhibiting its clearance, whereas other drugs may inhibit the anticoagulant effect by 
enhancing its clearance. [12]  
 
Drugs can also indirectly influence the pharmacodynamics of phenprocoumon by 
inhibiting the synthesis or by increasing the clearance of vitamin K-dependent 
coagulation factors or by interfering with other pathways of haemostasis. [16] 
Theoretically, antibiotics may augment the anticoagulant effect of phenprocoumon in 
patients by eliminating bacterial flora and aggravating vitamin K deficiency. [40] 
 
Pharmacogenetic Influences 
Other inter-individual variations such as pharmacogenetic predisposition can affect 
the amount of coumarin anticoagulants required. Therefore, pharmacogenetic plays 
an important role in safety and effectiveness of VKAs.  
There are two key structures which may influence the concentration and/or the 
activity of phenprocoumon: The cytochromeP450 system (affecting 
pharmacokinetics) and vitamin K-epoxid reductase (affecting pharmacodynamics). 
[41-42] 
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Cytochrome P450 (CYP) is a group of hepatic microsomal enzymes which act as 
monooxygenases. Cytochromes transform lipophilic drugs into more hydrophilic 
metabolites which facilitates further elimination and renal excretion. The gene 
CYP2C9 encodes the enzyme CYP2C9, of which about 30 variant alleles have been 
described.  
The gene VKORC1 encodes vitamin K-epoxid reductase (VKORC1), of which 
several variant alleles have been described. VKORC1 recycles vitamin K epoxide to 
vitamin K hydroquinone. Vitamin K hydroquinone is an essential cofactor for the 
maturation of the clotting factors II (prothrombin), VII, IX, and X. [16, 24, 43]  
Coumarin anticoagulant derivatives interrupt the vitamin K cycle by inhibiting 
VKORC1. (cf. figures 2, 4 and 5) [16, 24] 
 
Nevertheless, phenprocoumon metabolism appears to be less influenced by the 2C9 
genotypes when compared with other coumarin anticoagulants. [18, 41, 44] So, 
greater variability in dose requirement is observed by the VKORC1 genotype than by 
the CYP2C9 genotype. [45]  
 
Beside these direct influences on the pharmacokinetics and pharmacodynamics of 
phenprocoumon, mutations of other genes coding for proteins involved in drug 
metabolism or in the coagulation cascade may have more indirect effects on the 
intensity of anticoagulation. Single nucleotide polymorphisms (SNPs) of calumenin 
(CALU), microsomal epoxide hydrolase 1 (EPHX1), factor VII (F7), -glutamyl 
carboxylase (GGCX) and protein C (PROC), are potential candidates and their ability 
to interfere with phenprocoumon action has previously been studied. [41] 
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Calumenin has been shown to inhibit the activity of VKOR und GGCX. [46]  
EPHX1 is suspected to be a part of the vitamin K epoxide reductase complex. [47] 
(cf. figure 4) 
 
 
 
 
 
 
 
 
 
 
 
Figure 4: Interaction of phenprocoumon with the vitamin K-dependent -carboxylation system modified 
according to Luxemburg et al. [43]
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Phenprocoumon is Highly Bound to Albumin 
> 99% of phenprocoumon is bound to albumin (cf. table 1). Only the small (< 1%) 
unbound fraction of phenprocoumon is physiologically active and can be 
metabolized. Therefore, not only drug action but also drug elimination can be 
influenced by the serum concentration of binding proteins (mainly albumin). Since 
albumin is mainly intravascular the body-albumin content is determined by the 
product of albumin concentration and the plasma volume. This is sometimes referred 
to as “albumin space”. Plasma volume is essentially determined by body mass 
whereas many factors govern albumin concentration. Albumin synthesis is 
diminished in malnutrition or impaired liver function. However, albumin concentration 
can also be low in inflammatory states (acute-phase reaction) or in the presence of 
losses to the third space or the kidneys. In hypoalbuminaemia the initial loading dose 
of phenprocoumon is therefore expected to be lower due to the lower albumin space. 
On the other hand in patients with low serum albumin drug elimination is expected to 
be higher due to a higher fraction of unbound drug. Indeed, patients with liver 
cirrhosis and low serum albumin have a higher drug clearance than expected. [48-49] 
Several drugs can compete with the albumin binding of phenprocoumon. This is 
especially important at the onset of treatment with these drugs because even a small 
displacement of coumarins may substantially increase the biologically active 
unbound fraction. 
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Conceptual Model of Variable Phenprocoumon Dose Demands 
As outlined above, coumarins not only have a narrow therapeutic range but patients 
treated with coumarins also show substantial interindividual variability in drug 
requirements.  
Conceptually the factors controlling the variability of phenprocoumon requirement are 
summarized in figure 5. Some factors (e.g. age) have the potential to affect more 
than one pathway. The combined effects may be additive, subtractive, or even 
neutralizing. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5: Conceptional model of the influencing factors during anticoagulation with coumarins 
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The incidences of both bleeding and thromboembolic events increase sharply with 
advanced age. [10, 50-51] Alcohol consumption, liver disease and other unknown 
factors also influence optimal daily dosages. Enzymatic induction due to long-term 
alcohol consumption may increase the clearance of phenprocoumon. [16, 48] 
Other inter-individual variations which affect the metabolism and thus the optimal 
daily dosages include pharmacogenetic predisposition (VKOR-, -carboxylase-
activity) and weight. Indeed, Schwabedissen et al. found that the amount of 
phenprocoumon required during initiation of treatment was higher in obese patients. 
[52] 
 
Several risk factors for overanticoagulation have been identified, such as advanced 
age, female gender, drug and dietary interactions, and previous bleeding. [12] But 
also the intensity of the anticoagulant effect achieved and the presence of serious 
comorbid diseases, particularly cerebrovascular, kidney, heart, and liver disease, and 
concurrent medication may be independent risk factors. [7] 
 
Most of these factors mainly affect drug metabolism and thus the maintenance dose. 
During the initial rapid loading phase metabolism plays a minor role, whereas the 
volume of distribution is of primary interest. [52] Since coumarins are highly bound to 
albumin, the volume of distribution corresponds to the “albumin space”, i.e. blood 
volume multiplied by albumin concentration. Therefore, diverse factors may predict 
the loading dose as opposed to the maintenance dose of coumarins.  
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It is the goal to reach a stable therapeutic level of anticoagulation in due time and 
with a minimum of complications. If anticoagulants are started with an anticipated 
maintenance dose, a steady-state will not be reached before 5 half-lives. This may 
be acceptable for coumarins with short half-lives but is not feasible in most cases for 
phenprocoumon. As the risk of anticoagulant-related complications is highest at the 
start of an OA therapy, the search for an algorithm for the initial phase of the 
phenprocoumon therapy is expected to contribute to drug safety. 
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3 Aims of the Thesis 
The general aim was to define one or more algorithms for the loading phase of 
phenprocoumon-treatment. These algorithms should be easily applicable in a clinical 
setting and help to improve the drug safety of phenprocoumon in the initial dose-
finding process, which is presently largely empiric. 
In the retrospective study, algorithms were to be established to predict the loading 
dose of phenprocoumon for a target-INR of 2.0 to 3.0 in medical and orthopaedic 
inpatients.  
The prospective study was planned to validate and, if necessary, optimize these 
algorithms. Additionally, the predictive value of pharmacogenetic markers was to be 
studied. 
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4 Overall Summary of the Thesis 
Phenprocoumon is the second most commonly used oral anticoagulant worldwide 
and the most common agent in many European countries including Switzerland. 
Given its long half-life of about one week, an initial loading-dose is generally applied. 
A high loading-dose is helpful to rapidly reach a therapeutic concentration but may be 
associated with an increased risk of bleeding if the effect overshoots.  
Phenprocoumon has a narrow therapeutic range, and individual dose requirements 
are highly variable. In clinical practice the initial dose-finding process for 
phenprocoumon is largely empiric and often delegated to inexperienced staff 
members. Thus, both a prolonged loading phase and overshooting of anticoagulation 
is commonly observed. 
Question under study 
The general aim of the thesis was to define one or more algorithms for the loading 
phase of phenprocoumon-treatment. These algorithms should be easily applicable in 
a clinical setting and help to improve the drug safety of phenprocoumon especially 
during the initial dose-finding process. 
Retrospective study 
In a retrospective study, predictors of individual dosing needs for a target-INR of 2.0 
to 3.0 in medical and orthopaedic inpatients were determined. Several significant 
predictors of the loading dose could be identified. Using these predictors two simple 
clinical algorithms for the initial dosing of phenprocoumon in medical and orthopaedic 
inpatients were developed. One algorithm contains clinical data and, additionally, 
serum albumin; the second algorithm contains clinical data only. 
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Prospective study 
The aim of the prospective, randomized interventional study was to validate the 
efficacy and safety of the two previously proposed dosing algorithms for the initiation 
of oral anticoagulation with phenprocoumon. Additionally, the predictive value of 
pharmacogenetic markers was to be studied. 
Both algorithms could be validated and were slightly optimized. They proved to be 
very safe and effective in hospitalized patients with a high rate of comorbidity.  The 
algorithm using clinical data can be especially recommended due to its simplicity of 
use.  
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5 Methods, Results and Discussion 
The content of this dissertation is based on the subject of two publications. Thus, the 
following pages contain these two papers, starting with the retrospective study and 
continuing with the prospective study.
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Introduction 
In many countries phenprocoumon is predominantly used for oral anticoagulation. 
Given its long half-life of 110 - 130 h [1], an initial loading-dose is generally applied 
[2]. A high loading-dose is helpful to rapidly reach a therapeutic concentration but 
may be associated with an increased risk of bleeding if the effect overshoots. As 
other coumarins, phenprocoumon has a narrow therapeutic range and individual 
dose requirements are highly variable, but in contrast to Warfarin [3] no prediction 
rules for the initial loading phase are established. In clinical practice the initial dose-
finding process for phenprocoumon is largely empiric. The goal of our study was to 
define readily available predictors of the loading dose of phenprocoumon for a target-
INR of 2.0 to 3.0 in medical and orthopaedic inpatients. 
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Patients and methods 
Patients 
One year of consecutive inpatients of the medical department with new-onset oral 
anticoagulation and two years of patients undergoing hip or knee replacement 
surgery in the orthopaedic department of a 700-bed tertiary hospital in eastern 
Switzerland were retrospectively identified from electronic patient records. Clinical, 
drug and laboratory data were extracted by chart review and patient contact in case 
of missing data. Hospital food on average contained 185 g/day of vitamin K. 
Patients were excluded if they had been under oral anticoagulation less than 6 weeks 
prior to the index hospitalisation or if they received vitamin K supplements within one 
week before anticoagulation was started or during the loading phase. Patients were 
also excluded if the information on dosing and the INR-values was incomplete before 
the first INR  2.0 was reached, if they had liver cirrhosis > Child grade A, or surgery 
during the loading phase with phenprocoumon. The study was approved by the 
institutional data protection board. 
Predictors 
Patient factors (age, gender, height, weight, active alcohol or substance abuse, 
current smoking, diabetes, congestive heart failure, COPD, cholestasis, active 
cancer, malabsorption, and liver cirrhosis), acute conditions within one week prior to 
onset of anticoagulation (surgery, diarrhoea, vomiting, fever, sepsis, type of diet, and 
fasting periods), the last available laboratory values (creatinine, bilirubin, albumin, 
ALAT, AP, CRP, PTT, and INR), and drugs used within 2 weeks of onset of treatment 
(antibiotics, heparins and other anticoagulants, inhibitors of platelet aggregation,  
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nonsteroidal anti-inflammatory drugs, corticosteroids, and inducers as well as 
inhibitors of Cytochrome P-450 3A4 or P-450 2C9) were assessed. 
Outcome variables 
The main outcome variable was the cumulative dose of phenprocoumon to reach the 
target INR of 2.0 to 3.0. This dose was corrected in case of overshooting (> 3.5) INR 
or prolonged (> 5 days) dosing to reach the target INR. Secondary outcome 
measures were predictors of overshooting (> 3.5) INR, and predictors of a dose  
< 25th percentile. 
Statistics 
Statistical calculations were performed using SAS 8.2 (SAS institute, Cary, NC, 
USA). Continuous data are presented as medians and interquartile range, and 
compared using Wilcoxon’s test. Categorical variables are presented as percentages 
and compared using Fisher’s exact test. Two models for the loading dose of 
phenprocoumon were developed. One model contained albumin whereas the second 
model was without albumin, since in clinical practice this variable is often unavailable 
at the time of drug prescription. Irrespective of their statistical significance, we then 
added significant predictors of overshooting INR (> 3.5) and / or of low dose 
demands (< 25th percentile) to the model for the loading dose of phenprocoumon. 
These predictors were derived by logistic regression. 
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Results 
Baseline characteristics 
During the period of observation, oral anticoagulation was started in 223 medical and 
217 orthopaedic patients, all of whom were Caucasians. 71 medical and 69 
orthopaedic patients were excluded, mainly due to prior treatment with oral 
anticoagulants. The baseline-data of the remaining 152 medical and 148 orthopaedic 
patients are summarized in Table 1. 
Table 1: Baseline characteristics 
Variable Medical Orthopaedic p = 
N 152 148 n.s. 
Female sex   58 (38%)   89 (60%) <0.0001 
Age (years)   73 (61/80)   71 (62/77) n.s. 
Weight women (kg)   69 (60/76)   67 (60/79) n.s. 
Weight men (kg)   81 (70/90)   80 (70/92) n.s. 
BMI (kg/m
2
)   27.2 (24/29)   27.0 (24/31) n.s. 
    
Co-morbidity    
Active cancer   20 (13%)     6 (4%) 0.007 
Alcohol consumption > 2 drinks/day     9 (6%)     7 (5%) n.s. 
Cirrhosis Child A     0 (0%)     3 (2%) n.s. 
Clearance < 25 ml/min     7 (5%)     0 (0%) 0.01 
Congestive heart failure   36 (24%)     0 (0%) <0.0001 
Current smoking   30 (20%)   31 (21%) n.s. 
Diabetes mellitus   21 (14%)   14 (9%) n.s. 
Diarrhoea within 1 week   17 (11%)     2 (1%) <0.0005 
Fever > 38 °C within 1 week   24 (16%)     9 (6%) 0.01 
    
Laboratory values    
Albumin (g/l)   39 (35/41)   42 (40/43) <0.0001 
Clearance (ml/min)   70 (51/94)   69 (53/90) n.s. 
CRP   18 (5/65)     4 (3/7) <0.0001 
INR     1.0 (0.9/1.1)     1.0 (0.9/1.1) n.s. 
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Drugs    
Antibiotics   47 (31%) 148 (100%) <0.0001 
NSAIDs   16 (11%) 132 (89%) <0.0001 
Cox-2 Inhibitors     9 (6%)   35 (24%) <0.0001 
Inducers of CYP450 2C9     9 (4%)     3 (3%) n.s. 
Inducers of CYP450 3A4   37 (24%)   29 (25%) n.s. 
Inhibitors of CYP450 2C9   59 (39%)   97 (85%) <0.0001 
Inhibitors of CYP450 3A4   84 (55%)   68 (60%) n.s. 
Data are presented as number of cases and % or median and interquartile range. N = Number of 
cases, BMI = Body-mass index, CRP = C-reactive protein, INR = International normalized ratio, 
NSAIDs = Nonsteroidal anti-inflammatory drugs. 
 
Time-course of INR and phenprocoumon-dosing 
The corrected cumulative dose until the first therapeutic INR was reached was 
overall (median [interquartile range]) 18.0 [14.75 - 24.0] mg. Orthopaedic patients 
needed substantially lower doses (15.75 [12.00 - 18.75] mg) than medical patients 
(21.0 [16.5 - 26.25] mg; p<0.0001). 
Predictors of cumulative loading dose 
The best model for the loading dose included weight, albumin, self-reported alcohol 
consumption exceeding 2 drinks/day, age over 60 years, and an operation within a 
week. This model explained 34% of the variance (R2). 
Predictors of overshooting INR and of phenprocoumon-needs < 25th percentile 
After adjustment for age, weight, albumin, operation and alcohol consumption as well 
as the dose of phenprocoumon within the first three days, the following variables 
evolved as significant predictors of overshooting (> 3.5) INR: female gender (Odds 
ratio [OR] = 2.3; 95% Confidence interval [95%CI] = 1.1 - 4.7), creatinine clearance 
below 25 ml/min (OR = 6.6; 95%CI = 1.04 - 41) and diarrhoea (OR = 5.4; 95%CI = 
1.7 - 17). Similarly, clearance below 25 ml/min (OR = 8; 95%CI = 1.5 - 44), diarrhoea  
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(OR = 3.8; 95%CI = 1.04 - 14), and higher initial INR (OR = 1.5; 95%CI = 1.08 - 2.0 
for each 0.1 increase in INR) were significant predictors of a cumulative dose below 
the 25th percentile. For safety reasons the final model was extended by the above-
mentioned factors associated with unusually low phenprocoumon demands or 
overshooting INR irrespective of their statistical significance. 
Albumin measurements are often unavailable when the first three doses of 
phenprocoumon are prescribed. Higher age correlates with lower albumin and is a 
significant predictor risk of overshooting INR. We therefore substituted age for 
albumin in this situation. This model had an explanatory power of 33% (Table 2). 
Table 2: Two models to predict the total loading dose (mg
*
 for 5 days) 
Variable 
Model using 
Albumin 
Model using 
Age 
 Effect p = Effect p =  
Intercept of regression model 6.7 – 17.0 – 
Weight (per kg) 0.12 <0.0001 0.12 <0.0001 
Albumin (per g) 0.20 0.02 – – 
Age (per year) – – –0.07 0.007 
Age > 60 years –1.6 0.05 – – 
Alcohol > 20 g / d 2.7 0.05 3.5 0.02 
Operation –6.2 <0.0001 –5.6 <0.0001 
Predictors of the corrected cumulative loading dose (on average 5 days) of phenprocoumon. The first 
model needs a recent albumin value, the second model assumes that no albumin value is available. 
Both models are adjusted for gender, first INR, creatinine-clearance, and diarrhoea.  
n.s. = Not significant, p = Probability, INR = International normalized ratio. 
* 1 pill of phenprocoumon corresponds to 3 mg. 
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Most clinicians prescribe the first three doses of phenprocoumon empirically and 
adjust the further doses according to an INR measured on day four.  
In line with this clinical habit we propose two algorithms for the empiric dose-
estimation: 70% of the predicted loading dose is prescribed within the first three days  
and a standardized dose-escalation scheme is provided for the subsequent days 
according to the INR value on day four. This dosing algorithm has not yet been 
prospectively validated. (Figs. 1 – 3) 
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Albumin (g/l) 
+ 
Correction for comorbidity 
 < 20 21 - 30 30 - 40 > 40 Alcohol > 20 g/day + 1 pill 
< 45 3 4 4 5 Operation within 1 week – 2 pills 
45 – 60 4 4 5 5 Any combination of 
- age > 60 
- female sex 
- diarrhoea 
- baseline-INR > 1.2 
- clearance < 25 ml/min 
– 1 pill 
60 – 75 4 5 5 5 
75 – 90 5 5 5 6 
> 90 5 5 6 6 
 
Figure 1: Number of pills
*
 for the first three days if albumin is available. To obtain the empiric dose for 
the first three days the number of pills is determined on the left hand side at the intersection of the 
patient’s albumin and weight. This dose is further adjusted in the presence of comorbidity or female 
gender. This dose is then subdivided according to the nomogram in Fig. 3. 
* 1 pill of phenprocoumon corresponds to 3 mg. 
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 < 40 40 - 60 60 - 80 > 80 Alcohol > 20 g/day + 1 pill 
< 45 5 4 4 3 Operation within 1 week – 2 pills 
45 – 60 5 5 4 4 Any combination of 
- female sex 
- diarrhoea 
- baseline-INR > 1.2 
- clearance < 25 ml/min 
– 1 pill 
60 – 75 5 5 5 4 
75 – 90 6 5 5 5 
> 90 6 6 5 5 
Figure 2: Number of pills
*
 for the first three days if albumin is not available. To obtain the empiric dose 
for the first three days the number of pills is determined on the left hand side at the intersection of the 
patient’s age and weight. This dose is further adjusted in the presence of comorbidity or female 
gender. This dose is then subdivided according to the nomogram in Fig. 3. 
* 1 pill of phenprocoumon corresponds to 3 mg. 
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Empiric dose 
INR after 3 doses 
< 1.5 1.5 – 2.0 2.1 – 3.5 > 3.5 
Day 1 Day 2 Day 3 Day 4 Day 5 Day 4 Day 5 Day 4 Day 5 Day 4 Day 5 
 2.0 1 ¾  ¼  2 1 ½  ¼ 0 ¼ 0 0 
  3.0 1 ½ 1 ½  2 1 ½ ½ 0 ¼ 0 0 
  4.0 2 1½ ½  2 2 ¾ ¾ ¼ ¼ 0 0 
  5.0 2 2 1 2 2 ¾ 1 ¼ ¼ 0 0 
 6.0 3 2 1 2 2 1 1 ¼ ¼ 0 0 
Figure 3: Nomogram for empiric initial dosing of phenprocoumon. The number of pills derived from 
Figs. 1 or 2 corresponds to the number in the leftmost column. All doses for a given patient are 
obtained from this specific row. The empiric doses for day 1 to day 3 are first prescribed and the INR 
is determined after three doses. The dosing for days 4 and 5 is then guided by the result of this INR.  
* 1 pill of phenprocoumon corresponds to 3 mg. 
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Discussion 
The loading-dose of coumarins has two main components: the saturation of the 
volume of distribution and the ongoing elimination during the loading period. Given 
the long elimination half-life of phenprocoumon of roughly one week, the loading-
dose is mainly dependent on the volume of distribution, which is 0.15 to 0.2 l/kg. 
Since 99% of phenprocoumon is bound to albumin [4] the volume of distribution 
correlates with plasma albumin concentration and plasma volume, which again 
depends on body weight. Indeed, albumin concentration and body weight resulted as 
the main predictors of the loading dose in our model. Our findings parallel those of 
others [5], who derived dosing algorithms for warfarin including weight and albumin. 
In contrast to warfarin, phenprocoumon-clearance is less affected by genetic 
polymorphisms of CYP450 [6]. Indeed, no significant effect of inducers or inhibitors of 
CYP450 2C9 or 3A4 was found. 16 patients, however, who habitually consumed 
more than 20 g alcohol (2 drinks) per day prior to hospital admission on average had 
a 3 mg higher demand of phenprocoumon. Induction of the cytochrome-P450 system 
is the most likely reason for this effect. This hypothesis is in line with data from 
Penning-van Beest and co-workers, who identified a decrease in alcohol intake as an 
important risk factor for overanticoagulation [7]. 
Orthopaedic patients needed substantially lower doses of phenprocoumon than 
medical patients. The most obvious explanation is a lower albumin concentration in 
orthopaedic patients due to perioperative blood loss, and an operation-induced 
acute-phase reaction. In most orthopaedic patients albumin was only determined at 
hospital admission, i.e. one day before surgery.  
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Orthopaedic patients also more commonly took NSAIDs or Cox-2 inhibitors, which 
can compete with albumin-binding sites. 
Finally, perioperative fasting and perioperative antibiotic prophylaxis may have 
decreased the intake of vitamin K or its production by intestinal bacteria [8]. 
Older age, female gender, diarrhoea, higher baseline INR, and low creatinine-
clearance were independent predictors of lower phenprocoumon-needs or 
overshooting INR. Caloric intake decreases with older age and with it the intake of 
vitamin K. Moreover, drug metabolism decreases with age [4]. Women have a lower 
plasma-volume than men of similar weight due to a different body composition. 
Patients with diarrhoea often eat less due to nausea, and the production of vitamin K 
by intestinal bacteria and its resorption may be reduced due to accelerated intestinal 
transport. Higher baseline INR can indicate malnutrition, impaired liver function, or a 
coagulation disorder and thus warrants careful dosing of coumarins. Persons with 
impaired kidney function often show a reduced caloric intake and with it a reduced 
intake of vitamin K. Furthermore, a higher fraction of coumarins remains unbound to 
albumin in kidney disease since uraemic toxins compete with it at the same binding 
site [9].  
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Study limitations 
The present study only included hospitalised patients, which limits its generalizability. 
In clinical experience outpatients tend to need higher doses than inpatients. An 
algorithm derived from our data is therefore likely to predict somewhat conservative 
doses for outpatients. In our analysis we also did not test for polymorphisms of 
CYP450 2C9 or the VKORC1 gene, which are responsible for substantial variations 
in dose requirements [10]. Genetic profiling may become more widely available in the 
future but it is expensive and – especially in an ambulatory setting – the result will not 
arrive in due time to influence the first prescription of coumarins. Oral anticoagulation 
will therefore still often be initiated empirically with dose-adjustment according to 
INR-values. 
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Summary 
Question under study 
Prospective validation of two algorithms for the initiation of phenprocoumon treatment 
Methods 
Inpatients with new-onset anticoagulation were randomized to one of two computer 
assisted dosing algorithms, or to a control arm. The primary outcome measure was 
the time to achieve therapeutic anticoagulation without overshooting (INR > 4.0 within 
10 days). Secondary outcomes included overshooting INR-values, death, or bleeding 
within 30 days. In addition, predictors of the dosing algorithms for the loading dose 
and the maintenance dose including genetic parameters were reassessed.  
Results 
105 patients were randomized to arm A, 103 to arm B, and 93 to the control arm. 
Arms A and B needed a median of 7 days to reach a therapeutic INR, arm C 6 days 
(p=0.5). Overshooting INR was observed in 3.8%, 1.9% and 4.3% respectively 
(p=0.6). Bleeding was found in 0%, 1.9%, and 5.4% (p=0.06) and 30-day mortality 
was 0%, 1%, and 2.2% respectively (p=0.2). VKORC1:c.-1639G>A was associated 
with lower loading doses whereas VKORC1:c.-1453G>A needed higher doses. 
VKORC1:c.-1639G>A was also associated with lower maintenance doses. 
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Conclusion 
Both algorithms allow a safe initial dosing of phenprocoumon but they are not 
superior to anticoagulation by trained physicians. Dosing aids for coumarins with 
readily available clinical parameters may nevertheless be helpful for the use in 
polymorbid hospitalized patients. Clinical data and the INR-response to treatment 
provides powerful information and delaying initiation of anticoagulation while awaiting 
genetic tests is not expected to increase drug safety. 
Key words 
randomized controlled trial; phenprocoumon; oral anticoagulation; coumarin; initiation 
of treatment; dosing; drug safety; hospital; pharmacogenetics; VKOR; loading dose, 
maintenance dose  
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Introduction 
Coumarin derivatives are still the drugs of choice for long-term treatment and 
prevention of thromboembolic events because they are cheap and highly effective for 
the treatment and prevention of deep venous thrombosis, pulmonary embolism, and 
embolic stroke. [1-3] In many European countries phenprocoumon is the 
predominantly used anticoagulant. The management of anticoagulation with 
phenprocoumon is challenging because of its narrow therapeutic range and large 
interindividual variation of dose demands. In addition, the onset of action is typically 
delayed due to the long half-life of the intact coagulation factors in the circulation. 
Unless an initial loading dose is given, the onset of action is further delayed due to a 
prolonged time to reach therapeutic drug levels owing to the long half-life (110 - 130 
h) of the drug. [4-6] The following main causes contribute to interindividual variability 
in dose demands: differences in the volume of distribution of phenprocoumon, 
differences in drug metabolism and differences in the concentrations of reduced 
(active) vitamin K.  
More than 99% of phenprocoumon is bound to serum albumin and only unbound 
coumarins contribute to the anticoagulant effect. Therefore, one main determinant of 
the loading dose is the total body albumin content, which has to be saturated during 
the loading phase 
In comparison, drug elimination by metabolizing enzymes is the main determinant of 
the maintenance dose because during steady state conditions the maintenance dose 
has to equal drug elimination.  
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Drug elimination depends on the activity of the metabolizing enzymes which can vary 
with age, drug interactions or genetic factors as the CYP 450 genotype. [7-11] 
However, variable drug requirements can also be caused by differences of drug 
susceptibility at the site of action. One central pharmacodynamic factor for coumarins 
is the availability of reduced vitamin K which depends on diet but also on the activity 
of vitamin K epoxide reductase complex 1 (VKORC1). [12] Single-nucleotide 
polymorphisms (SNPs) of this gene have been shown to reduce the activity of this 
enzyme. [13-16] Several other allelic variants of genes have been proposed to be 
associated with either altered drug elimination or drug susceptibility. [7, 13, 16-23] 
Given the complexity of these issues, inexperienced physicians often have difficulties 
to safely initiate treatment with phenprocoumon. A model to predict the loading dose 
with phenprocoumon is therefore desirable. Once a steady-state has been reached, 
future doses will be more easily predicted based on the response to past doses. In a 
retrospective study of 300 medical and orthopaedic inpatients we previously 
developed two dosing algorithms for the initiation of anticoagulation with 
phenprocoumon based on clinical predictors such as age, body weight, and readily 
available laboratory values. [24] The aim of this prospective, randomized 
interventional study was to validate the efficacy and safety of the two dosing 
algorithms compared to “conventional dosing” by staff physicians in medical and 
orthopaedic inpatients. Further aims were to improve these algorithms and to assess 
the additional predictive value of genetic markers. 
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Patients and Methods 
This was a single-centre, randomized, and controlled study of two algorithms for the 
initiation of phenprocoumon. All medical inpatients irrespective of the indication for 
anticoagulation and patients undergoing hip or knee replacement surgery of the 
orthopaedic department of the St. Gallen Cantonal hospital, a 700-bed tertiary care 
hospital in eastern Switzerland, with new-onset oral anticoagulation were eligible for 
participation in the study. Recruitment took place between January 2007 and 
December 2009. Patients were excluded if they had been under oral anticoagulation 
less than 6 weeks prior to the index hospitalisation or if they received vitamin K 
supplements within one week before anticoagulation was started. Patients were also 
excluded if they were younger than 18 years, pregnant, unwilling or unable to give 
informed consent, had liver cirrhosis other than Child grade A, contraindications to 
anticoagulation, or insufficient communication skills in German, French, Italian, or 
English. The study was approved by the institutional review board.  
Patients were automatically randomized to one of three arms without stratification 
using a computer-based system integrated in the clinical information system 
Phoenix(R) (Parametrix, Lachen Switzerland). In arm A phenprocoumon was dosed 
using the algorithm based on albumin and clinical data, in arm B using the algorithm 
based on clinical data only, and in arm C dosing was at the discretion of the 
physicians. The algorithms have been described elsewhere. [24] In brief the dose-
finding process was made using the same variables (except for amiodarone) as 
outlined in figure 4 of the present article for arm B. The algorithm for arm A was 
identical to arm B except for the categorical use of albumin instead of age in the left-
hand table and an additional dose-reduction for age > 60 in the ‘comorbidity’-list.  
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For arms A and B, the computer program provided doses for three days on day 1, 
and when the INR of day 4 was entered, the system provided doses for the next two 
days. The review board requested that all participating physicians were trained about 
best practice of anticoagulation. Furthermore, patients with concomitant anti-platelet 
treatment (mainly aspirin and/or clopidogrel) and patients within one week after 
orthopaedic operations were only allowed to receive a cumulative maximum dose of 
3 pills (3 mg per pill) during the first 3 days due to safety concerns. Clinical, drug and 
laboratory data were extracted by chart review. After 30 days patients were 
contacted and asked to provide a copy of the anticoagulation booklets (doses and 
INR). If the booklets were not available from patients, their physicians were contacted 
and asked to provide information on clinical course and INR values. Treating 
physicians were also asked to obtain blood for genetic analyses. Unfortunately this 
blood was only provided for about half of the patients. Genetic analyses were 
performed as previously described. [16, 25] As long as the patients were 
hospitalized, INR was measured from citrate plasma using the thromboplastin 
reagent Recombiplastin 1 (Axon Lab AG, Baden, Switzerland) on the automated 
coagulation analyzer ACLTOP 700 LAS (Axon Lab AG, Baden, Switzerland). After 
discharge INR-measurements were usually performed by family physicians. 
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Outcome parameters 
Outcome parameters were assessed by chart review. The primary outcome measure 
of the prospective study was the time to achieve therapeutic anticoagulation (loading 
phase) without consecutive overshooting of INR. Secondary outcomes included 
overshooting INR-values, death, or bleeding within 30 days. The duration of the 
loading phase was defined as the number of days to reach the first INR > 1.9. 
Bleeding during anticoagulation was the main adverse outcome variable. Major 
bleeding was defined as death due to bleeding, intracranial haemorrhage, need for 
(re-)operation, drop of haemoglobin by > 20g/l and/or the need for blood transfusions. 
All other bleeding episodes were considered to be minor. Overshooting of INR 
attributed to the loading dose was defined as an INR > 4.0 within 3 days after the 
loading phase.  
In addition, predictors of the dosing algorithms for the loading dose and the 
maintenance dose including genetic parameters were reassessed. Since we 
intended both a safe and a rapid loading phase, the goal was to achieve therapeutic 
INR values within about one week without overshooting. We therefore had to 
estimate the ideal individual loading dose, which would result in a therapeutic INR if it 
was given within 6 days in the same patient in a similar situation. If a therapeutic INR 
was reached by this time, the observed cumulative dose directly equalled the 
individual loading dose. If the loading phase was prolonged or if overshooting of INR 
was observed, the observed cumulative dose had to be corrected for drug 
metabolization during this prolonged period or overdosing as previously described. 
[24] 
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The individual maintenance dose was defined as the average daily dose in a stable 
phase of therapeutic anticoagulation after the loading phase. 
Statistics 
In our retrospective study 58% of patients reached therapeutic INR levels without 
overshooting or complications within one week. In order to detect a 15% change of 
this endpoint with a power of 80% a sample size of 155 patients for each study arm 
was determined. Categorical variables are expressed as absolute numbers, rates or 
percentages and compared using Fisher’s exact tests. Continuous variables with 
approximate normal distributions are expressed as means and standard deviation 
and compared using Student’s t-Tests or ANOVA (if more than two groups were 
compared). If normality was questionable, they are presented as medians and 
interquartile range and compared using Wilcoxon’s Rank-Sum Tests or Kruskal-
Wallis Tests respectively. Missing information for genetics and doses were 
considered to be missing at random. This assumption was corroborated by a 
comparison of loading doses and maintenance doses between patients with and 
without genetic variables which yielded no statistical differences. The models from 
our derivation algorithms were repeated by linear regression and assessed for their 
explanatory power using the adjusted R2. New parsimonious models both for the 
individual loading dose and the individual maintenance dose were derived separately 
with and without genetic information using a backward selection method. Additional 
models using the predicted dose for the first three days and the most recent available 
INR were further built for days 4 and 6 in order to define the residual dose demands 
at these time points. INR measurements and phenprocoumon doses were used as 
time-dependent variables.  
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All other variables (age, gender, height, weight, active alcohol abuse, current 
smoking, diabetes, congestive heart failure, COPD, cholestasis, active cancer, 
malabsorption, vomiting, diarrhea, and liver cirrhosis, albumin, creatinine, genetic 
information, and comedication (antibiotics, platelet inhibitors, corticosteroids, 
amiodarone, as well as inducers and inhibitors of the cytochrome P450 3A4 and/or 
2C9 within two weeks before the onset of anticoagulation)) were considered to be 
time-constant. Statistical calculations were performed using SAS 9.2 (SAS Institute, 
Cary, NC, USA). All significance-tests were two-sided with a p-value < 0.05 indicating 
statistical significance. 
Derivation of the revised dosing algorithm 
To avoid overdosing a conservative algorithm was chosen. Therefore, the dose for 
the first three days aimed at the 10th percentile of the loading doses for each group, 
and subsequent dosing steps aimed at the 25th percentile of the residual dose-
distribution at the respective time point. This approach was chosen because on day 
one the predictive power of the model was still low and thus the unexplained variation 
of loading doses was still broad. At each subsequent dosing step the biologic 
response of the INR to phenprocoumon could be incorporated into the models which 
substantially improved the prediction and reduced the residual variability of the 
remaining dose-demands. 
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Results 
Inclusion was attempted in 348 patients, and 301 patients were randomized to one of 
the management arms. An overview of the study protocol is presented in fig. 1. 
 
348 patients assessed for eligibility
11 excluded
7 unable to give informed consent
2 previous OAC
1 liver disease > Child A
1 participation in another study
30 declined to participate
1 death before randomization
5 physician’s wish
105 arm A (with albumin) 103 arm B (with clinical data) 93 arm C (control arm)
100 information on treatment 6 days
96 information on treatment 30 days
1  treatment discontinuation
1 due to surgery
4  incomplete information on treatment
2 treatment discontinuation
1 due to infection
1 OAC considered to be unnecessary
2  incomplete information on treatment
100 information on treatment 6 days
95 information on treatment 30 days
2 treatment discontinuation
1 due to bleeding
1 due to death
1 incomplete information on treatment
2 treatment discontinuation
1 due to surgery
1 OAC considered to be unnecessary
3 incomplete information on treatment
85 information on treatment 6 days
79 information on treatment 30 days
3 treatment discontinuation
2 due to death
1 due to surgery
3 incomplete information on treatment
5 treatment discontinuation
1 due to bleeding
4 OAC considered to be unnecessary
3 incomplete information on treatment
301 randomized to treatment arms
100% complete 30 day follow-up
on survival and complications
100% complete 30 day follow-up
on survival and complications
100% complete 30 day follow-up
on survival and complications  
Figure 1: Overview of the study protocol 
 
Due to slow recruitment especially in orthopaedic patients (N=110) more medical 
patients (N=191) were included and enrolment was stopped prematurely. The 
baseline characteristics were evenly distributed in all arms as outlined in table 1.  
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Table 1: Baseline characteristics 
 Arm A Arm B Control arm 
    
N 105 103 93 
Age  (years) 64.8 +/-15.7 68.1 +/-14.3 65.9 +/- 16.7 
Female gender 54 (51.4%) 57 (55.3%) 48 (51.6%) 
Weight  (kg) 77.6 +/- 16.7 80.2 +/- 21.9 78.5 +/- 17.9 
Orthopaedics 39 (37.1%) 43 (41.7%) 28 (30.1%) 
Internal Medicine 66 (62.9%) 60 (58.3%) 65 (69.9%) 
Operation within 7 days 39 (37.1%) 45 (43.7%) 29 (31.2%) 
Alcohol > 20g/day 9 (8.6%) 7 (6.8%) 11 (11.8%) 
eGFR  (ml/min) 82.6 +/- 34.4 82.1 +/- 42.4 80.1 +/- 38.8 
Diarrhea 9 (8.9%) 6 (5.8%) 7 (7.5%) 
INR before start  1.0 +/-0.10 1.0 +/- 0.09 1.0 +/- 0.08 
Albumin  (g/l) 34.8 +/- 6.5 33.4 +/- 5.8 33.8 +/- 6.0 
    
Tc-aggregation Inhibitors 29 (27.6%) 32 (31.1%) 28 (30.1%) 
Amiodarone 6 (5.7%) 3 (2.9%) 4 (4.3%) 
CYP450-2C9 Inhibitors 28 (26.7%) 22 (21.45) 29 (31.2%) 
CYP450 2C9 Inducers 1 (0.95%) 3 (2.9%) 5 (5.4%) 
CYP450-3A4 Inhibitors 23 (21.9%) 17 (16.5%) 21 (22.6%) 
CYP450-3A4 Inducers 30 (28.6%) 31 (30.1%) 23 (24.7%) 
Data are presented as numbers of cases and percent (%) within each arm or mean and standard 
deviation. N = number of cases, INR = international normalized ratio, eGFR = estimated glomerular 
filtration rate, CYP450 = cytochrome P450, arm A = arm using clinical predictors and albumin, arm B = 
arm with clinical predictors only. 
Performance of the algorithms 
The median (interquartile range) time to reach a therapeutic INR was 7 (5/11) days in 
arm A, 7 (5/12) days in arm B and 6 (3/12) days in the control arm (p=0.5). 
Overshooting INR due to an excessive loading dose (i.e. INR > 4.0 within 10 days 
after the start of treatment) was observed in 3.8% in arm A, 1.9% in arm B and 4.3% 
of patients in the control arm (p=0.6). No episode of these overshooting INRs was 
associated with complications. 30-days bleeding rate (minor and major) was 0%, 
1.9% and 5.4% respectively (p=0.06), and 30-days mortality was 0% in arm A, 1% in 
arm B and 2.2% in the control arm (p=0.2).  
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The reasons for death were congestive heart failure in a 91-year-old male in arm B, 
and in group C paraneoplastic pulmonary embolism in a 63-year-old male and 
retroperitoneal bleeding in a 72-year-old female. This retroperitoneal bleeding 
occurred with an INR of only 2.2 and without previous overshooting and was the only 
episode of major bleeding in the entire study within 30 days.  
 
The detailed analysis of the episodes with overshooting INR showed that in only one 
patient (with a max. INR of 4.1) the initial dose for day 1 to 3 provided by the 
algorithm was responsible for overshooting. This patient was later shown to be 
homozygous for the VKORC1:c.-1639 G>A variant. In contrast, overshooting could 
be attributed to the correction dose for days 4 and 5 provided by the algorithm in 5 
episodes. All these episodes occurred in patients who had had a low-dose prediction 
(2 to 4 pills) for days 1 to 3. In addition, 5 patients with overshooting INR were 
exposed to amiodarone. In multivariate models amiodarone was consistently but not 
statistically significantly associated with a lower loading dose (-0.35 pills; to convert 
pills to mg multiply by 3).  
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Clinical predictors of the loading dose and the maintenance dose 
The mean (+/-SD) loading dose was 8.2 (+/- 3.8) pills in medical patients and 7.1 (+/- 
3.4) pills in orthopaedic patients (p=0.04). In univariate analysis higher age, lower 
weight, female gender, a recent operation, low albumin, higher initial INR, and 
impaired kidney function were significant predictors of lower loading doses. The 
predictors of the maintenance dose were almost identical to the predictors of the 
loading dose with the exception of albumin, which did not reach statistical 
significance. On the other hand alcohol abuse was associated with a significantly 
higher maintenance dose whereas only a trend for a higher loading dose could be 
observed.  
 
Approximate position of table 2 (cf. p. 65) 
Genetic predictors of the loading dose and the maintenance dose 
The influence of genetic predictors on dose demands could only be evaluated in a 
subset of 143 patients. VKORC1:c.-1639 G>A was associated with significantly lower 
dose demands both for the loading dose and the maintenance dose. Heterozygous 
patients showed about 50% of the effect of homozygous persons. A polymorphism of 
the factor VII-gene F7:c.1238G>A was associated with a similar absolute reduction of 
the loading dose in homozygous persons as the above mentioned VKORC1 
polymorphism but was only present in the homozygous form in 4 patients which may 
explain the marginal statistical significance (p=0.05). In contrast, the polymorphism 
VCORC1:c.-1453 G>A was associated with significantly higher loading dose 
demands.  
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Approximate position of table 3 (cf. p. 66/67) 
Multivariate Models 
In multivariate analysis including clinical parameters only, age, weight, first INR and 
recent operations proved to be strong independent predictors of the loading dose. In 
contrast, neither serum albumin nor the remaining predictors included in the 
algorithms (diarrhea, female gender, kidney function) significantly improved the 
model. With the exception of gender the effect size of these factors was comparable 
to the derivation cohort, which suggests that the power may have been insufficient to 
corroborate a true effect. When genetic tests were added, both the VKORC1:c.-1639 
G>A (associated with lower loading doses) and the VKORC1:c.-1453 G>A variants 
(associated with higher loading doses) proved to be additional significant predictors 
of the loading dose. The explanatory power of the model (adjusted R2) increased 
from 19% to 37% after the addition of genetic tests. 
 
Table 4: Multivariate predictors of loading dose (clinical predictors only) 
Factor  
Effect on Loading 
Dose (pills) 
95% CI p= 
Intercept 12.60   
Age (per 10 years older) -0.38 -0.73 to -0.05 0.03 
Weight (per 10 kg higher)  0.72 0.45 to 0.98 <0.0001 
INR before start (per 0.1 higher)  -0.69 -1.19 to -0.19 0.008 
Recent operation -1.93 -2.93 to -0.92 0.0002 
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Table 5: Multivariate predictors of loading dose including genetic tests 
Factor  
Effect on Loading 
Dose (pills) 
95% CI p= 
Intercept 12.29   
Age (per 10 years older)  -0.42 -0.78 to -0.05 0.02 
Weight  (per 10 kg higher)  0.66 0.37 to 0.94 <0.0001 
INR before start (per 0.1 higher)  -0.54 -1.09 to 0.02 0.06 
Recent operation  -1.28 -2.32 to -0.25 0.02 
VKORC1:c.-1639G>A AA 
  GA 
-3.50 
-0.72 
-4.87 to -2.14 
-1.84 to 0.39 
<0.0001 
0.2 
VKORC1:c.-1453G>A GA  3.50 1.29 to 5.71 0.002 
 
Higher age and lower weight were also independent predictors of a lower 
maintenance dose. The strongest predictor was, however, the number of pills needed 
to reach the first therapeutic INR. Among the genetic tests only the VKORC1:c.-1639 
G>A polymorphism proved to be an additional significant predictor of lower 
maintenance doses. Yet the explanatory power of the model only increased from 
55% to 57% when this genetic test was added. 
 
Table 6: Multivariate predictors of maintenance dose (clinical predictors only) 
Factor  
Effect on 
Maintenance Dose 
(pills) 
95% CI p= 
Intercept 0.343   
Age (per 10 years older) -0.040 -0.06 to -0.02 <0.0001 
Weight  (per 10 kg higher)  0.037 0.02 to 0.05 <0.0001 
Pills needed to reach first INR ≥ 2.0 0.024 0.02 to 0.03 <0.0001 
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Table 7: Multivariate predictors of maintenance dose including genetic tests 
Factor  
Effect on 
Maintenance Dose 
(pills) 
95% CI p= 
Intercept  0.28   
Age (per 10 years older)  -0.04 -0.07 to -0.02 0.001 
Weight (per 10 kg higher)  0.07 0.05 to 0.09 <0.0001 
Pills needed to reach first INR ≥ 2.0 0.015 0.01 to 0.02 <0.0001 
VKORC1:c.-1639G>A AA 
 GA 
-0.20 
-0.10 
-0.30 to -0.10 
-0.17 to -0.02 
0.0002 
0.01 
 
Dose estimation as a dynamic process  
Dose estimation is a multistep dynamic process in clinical practice. Therefore, static 
models to predict dose-demands can be helpful to cautiously start anticoagulation but 
with each INR measurement the biologic response to the administered doses 
provides strong additional information on future responses. Phenprocoumon is 
typically started with a prescription for the first three days followed by INR-
measurement and re-prescription every two to three days until the individual 
maintenance dose is found and controlling intervals can be prolonged. We therefore 
computed models for the remaining loading dose and the maintenance dose for days 
4 and 6. Age and weight, the cumulative applied dose and the INR at each respective 
time point allowed gradually more precise dose estimations. Given that all these 
factors already contributed to define the starting dose (i.e. the “row” in the table of the 
algorithms) we used this starting dose in subsequent models in order to simplify the 
correction algorithms. On day 4 both the starting dose and the INR were strong 
individual predictors of the residual loading dose demand. On day 6 only the INR 
remained a significant predictor of the residual loading dose in the subset of patients 
who had not yet reached a therapeutic INR (see figures 2 and 3).  
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In contrast, both the starting dose and the INR were significant predictors of the 
maintenance dose at both time points (see figures 2 and 3). 
 
  
Figure 2: Prediction of the residual loading dose on days 4 and 6 
  
Figure 3: Prediction of the maintenance dose on days 4 and 6 
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Revised algorithm 
Based on these findings three changes were made to the previous algorithm:  
i) amiodarone was added to the dose-reduction scheme for days 1 to 3, ii) the 
correction dose according to the INR on day 4 was slightly modified for the lower 
dose groups and iii) since the predicted residual doses and the maintenance doses 
on days 4 and 6 were very similar the dosing table for day 4 was extended to be valid 
on day 6. As outlined in the methods section these algorithms do not attempt to 
predict the most likely average dose but aim at a slightly lower dose and a stepwise 
approach to the individual dose without overshooting (see figures 4 and 5).  
 
Figure 4: Revised dosing algorithm for day 1 
 
Figure 5: Revised dosing algorithm for days 4 and 6 
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Table 2: Univariate clinical predictors of loading dose and maintenance dose 
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Table 3: Univariate genetic predictors of loading dose and maintenance dose 
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Table 3: Univariate genetic predictors of loading dose and maintenance dose 
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Discussion 
The main goal of this study was to test the effectiveness of two different dosing 
algorithms for the loading phase of phenprocoumon. Indeed both algorithms allowed 
classifying patients into groups with low, intermediate or high phenprocoumon 
demand on the basis of readily available parameters such as age, weight, a recent 
operation, or the last INR measurement. Both algorithms were safe and no major 
complication could be attributed to the proposed dosing regimens. A few patients 
showed a moderate overshooting of INR-values owing to a too high correction dose 
for days 4 and 5 in the groups which were predicted to require low initial dosing. 
Importantly, patients who showed early overshooting of the INR were often exposed 
to amiodarone. In multivariate models amiodarone was associated with lower loading 
doses; however, this was not statistically significant, presumably due to insufficient 
power of this small subgroup. Amiodarone is associated with lower coumarin 
demands due to its inhibition of CYP450 3A4 and 2C9. Accordingly, it is also included 
in dosing algorithms for warfarin. [26-32] As a consequence, we propose to include 
amiodarone into the revised algorithm and to make a slight modification of the 
correction dose on day 4. 
Nevertheless, the control arm, in which dosing was at the discretion of the hospital 
residents, performed similarly well as the two algorithmic arms. 30-day mortality was 
2.2% in the control arm (as opposed to 0% and 1% in arms A and B, respectively) 
and the 30-day bleeding-rate was 5.4% in the control arm (as opposed to 0% and 
1.9% in arm A and B). Yet these differences did not quite reach statistical 
significance possibly due to insufficient power of the study.  
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It could therefore be assumed that dosing algorithms for phenprocoumon are 
unnecessary or even useless. However, it has to be kept in mind that the study 
physicians were especially trained on optimal dosing and management of 
phenprocoumon on request of the institutional review board. The control arm may 
therefore have performed worse without training. Indeed in our retrospective study 
[24] in the same hospital and with an equivalent patient population we found 
substantially higher rates of overshooting INRs and complications especially in 
orthopaedic patients. In the advent of newer anticoagulants the experience with 
phenprocoumon will decrease despite a subgroup of patients who may still need the 
drug. Therefore, we conclude that both algorithms are safe and effective in a broad 
spectrum of hospitalized patients including patients in the postoperative setting and 
since the proposed algorithms performed at least as well as especially trained 
physicians, they may be of particular value for less experienced physicians.  
Algorithm A contains serum albumin as a major predictor which is not always 
available when the first dosing decision has to be made. In contrast, algorithm B, 
which performed equally well as algorithm A, contains mainly clinical data and in the 
multivariate analysis albumin was no longer an independent predictor of both the 
loading and the maintenance dose. Therefore, algorithm B seems to be preferable 
because of its ease of use.  
Polymorphisms of genes involved in vitamin K metabolism further improve the 
prediction of the loading dose in our models. In multivariable models VKORC1:-
c.1639G>A was a potent predictor of lower loading doses, which is in line with 
previous studies. [13, 16, 33-34]  
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In contrast, VKORC1:c.-1453G>A predicted higher loading doses. This is the first 
study to demonstrate a significant effect of this relatively rare polymorphism. Both 
polymorphisms are located in the promotor region of the VKORC1-gene, which 
suggests that these effects are mediated by altered gene expression. The 
explanatory power (adjusted R2) of the baseline model for the loading dose 
substantially increased from 19% to 37% after the addition of the two genetic tests. 
Therefore, if genetic tests were available on the first day, they could accelerate the 
dose-finding process. Yet genetic information is rarely available before the start of 
treatment and we could demonstrate that treatment can nevertheless be safely 
started using our algorithm. Therefore, delaying treatment while awaiting the result of 
a genetic test is not warranted. However, genetic information is more likely to be 
available on day 4, when the second dose decision is usually made. Yet, on day 4, 
the clinical model (including a recent INR) could already explain 55% of the variance 
and the addition of genetic tests only improved the model prediction to 57%. In other 
words the biologic response of the INR to the first three doses comprises powerful 
dynamic information on individual dose demands, and the additional static 
information provided by genetic tests is almost negligible once treatment has been 
started. Therefore, instead of adding costs and complexity by additional tests, the 
management of anticoagulation can be improved to a greater extent, if the 
information included in the INR response to treatment at each time-point and in each 
subgroup of patients is integrated in an evidence-based dosing decision.  
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Conclusions 
We could demonstrate that both algorithms are associated with safe and effective 
anticoagulation in a broad spectrum of hospitalized patients including postoperative 
states. Both algorithms were equally effective but the algorithm without serum 
albumin is easier to apply. Although the proposed algorithms did not perform better 
than especially trained physicians, they may be of particular value for less 
experienced physicians. We propose to include amiodarone into the dose estimation 
for days 1 to 3 and to slightly modify the correction algorithm for days 4 and 6.  
Limitations 
The present study only included hospitalised patients of predominantly Caucasian 
origin which limits the generalisability to outpatients and other racial groups. 
However, due to the higher prevalence of disease in inpatients it is unlikely that the 
algorithms would result in overdosing in outpatients. We propose to use the revised 
correction algorithm for day 4 also on day 6 although it has not yet been 
prospectively validated. However, dose-demands for the same INR were consistently 
slightly higher on day 6 than on day 4, which makes overdosing very unlikely. A 
larger study sample could have improved the power to detect group differences. This 
holds especially true for genetic predictors which were only available in about half of 
the patients. 
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6 Conclusions 
Clinical management of anticoagulation with coumarins is difficult, as a target range 
has to be achieved by drugs with a narrow therapeutic range and high intra-individual 
and inter-individual variability in pharmacokinetic and pharmacodynamic responses. 
The importance of maintaining coumarin users within the therapeutic range is driven 
by the aim of preventing thromboembolic events and by the necessity to minimize the 
risk of serious bleeding, the main manifestation of coumarin toxicity. 
In hospitalized patients this problem is even more acute because:  
i) these patients have a higher burden of disease than outpatients, which is 
likely to broaden the range of dose requirements,  
ii) they are also more often exposed to comedication and nutritional changes, 
which increases the risk of interactions or of low vitamin-K levels, 
iii) they undergo invasive procedures more often, which is expected to 
increase the complication rate,  
iv) less time is available to observe responses, and  
v) many decisions are made by inexperienced staff members.  
In order to provide an applicable tool to guide the dosing of coumarins, readily 
available information is required. 
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The general aim of the thesis was to define dosing algorithms for phenprocoumon 
which can easily be implemented in clinical practice. These algorithms should help to 
improve the drug safety of phenprocoumon in the initial dose-finding process which 
was until now largely empiric.  
Retrospective study 
In our retrospective study we could identify individual predictors of the loading dose 
from which we developed two clinical algorithms for the initial dosing of 
phenprocoumon in medical and orthopaedic inpatients. One algorithm contains 
clinical data and additionally serum albumin; the second algorithm contains clinical 
data only. The algorithm containing albumin performed slightly better in the 
retrospective analysis but it is less practical to apply because albumin is not always 
available when the first dosing decision (usually for days 1 to 3) has to be made. 
Prospective study 
In our prospective study both algorithms could be validated and were slightly 
optimized. Both algorithms proved to be very safe and essentially equivalent. The 
algorithm using clinical data only is preferable simply because it is easier to apply 
than the algorithm also using albumin. The institutional Review Board demanded a 
special training for study physicians. This introduced an inevitable source of bias into 
the study design. Presumably as a consequence of this training the algorithms 
proved not to be superior to dosing by the specially trained study physicians in a 
control arm. Although the data are not directly comparable, these results are in 
strong contrast to the result of our observational data in the retrospective study,  
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where we found a much higher rate of overshooting INR values and bleeding 
complications.  
In summary, both algorithms are safe and effective in hospitalized patients with a 
high rate of comorbidity. The algorithm using clinical data can be especially 
recommended due to its simplicity of use.  
As an extension of these studies which had the principal aim of defining a loading 
dose and a focus on the first six days of treatment, we additionally derived precise 
dosing information even for extended loading periods and an algorithm for the 
maintenance dose. In a nested sample of these patients we further assessed the 
additional predictive value of pharmacogenetic markers both for the loading dose and 
the maintenance dose. 
We chose a stepwise, conservative approach to find the target-INR without 
significant overanticoagulation. Even in the absence of information on genetic 
polymorphisms or previous dose demands, each patient can be reliably allocated to a 
stratum of low, intermediate or high drug demand by using readily available clinical 
information. This allows the a priori stratification of the dose for the first three days. 
Later on, the INR-response to this semi-empiric dose is a very potent predictor of 
future dose demands. A minimal response predicts much higher dose demands to 
reach a therapeutic level of anticoagulation whereas a steep rise of the INR indicates 
minimal residual dose demands. Similarly, the INR-response to subsequent doses 
becomes the main determinant of the maintenance dose.   
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Although these findings seem to be rather trivial, the strength of our studies lies in the 
structured approach and the provision of a simple and effective tool for inexperienced 
physicians.  
 
Genetic Testing 
The availability of genotypic information prior to administration of the first OA dose is 
not feasible for most patients at the moment. Genetic profiling may become more 
widely available in the future but it is expensive and – especially in an ambulatory 
setting – the result will not arrive in due time to influence the first prescription of 
coumarins. Even if genetic testing is ordered, oral anticoagulation will therefore often 
be initiated empirically with dose-adjustment according to INR-values. Delaying 
initiation of OA therapy is not an option as this is likely to delay discharge, prolong 
the use of heparins in ambulatory patients and increase healthcare costs.  
Pharmacoeconomic evaluations of pharmacogenetic testing suggest that genotype-
guided dosing for Warfarin therapy is not cost-effective. [1-2] This was the main 
factor for holding back a general recommendation of genetic screening for patients 
on anticoagulant therapy.  
We and others [3-9] could confirm that genetic variants are also significantly 
associated with phenprocoumon dose demands both during the loading and the 
maintenance phase. As outlined above, genetic information would ideally be most 
helpful at the time of the first dosing decision. At later time points the value of genetic 
information is rapidly compensated by functional information provided by  
the response of the INR to dosing.  
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Indeed, in our nested study with genetic markers the explanatory effect of these 
markers waned in multivariate analysis.  
 
However, if genetic information were available right at the beginning, it could 
substantially add to the dose prediction. The genes of one human being do not 
change during a lifetime, therefore genetic analysis theoretically only needs to be 
done once. We were able to demonstrate that even with the absence of genetic tests, 
dosing is safe with the use of a standardized approach. If our algorithm is used, 
pharmacogenetic testing before initiating coumarin oral anticoagulants may thus 
accelerate the time to reach the therapeutic goal.  
 
Limitations of the Retrospective and Prospective Study 
The present studies only included hospitalised patients of predominantly Caucasian 
origin, which limits their generalizability to outpatients and other racial groups. 
However, due to the higher prevalence of disease in inpatients it is unlikely that the 
algorithms would result in overdosing in outpatients who are generally less 
vulnerable.  
Our prospective study was limited to the loading phase. Further studies are needed 
to validate the proposed dosing algorithms during the maintenance phase. 
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Recommendations 
We strongly recommend using an evidence-based approach to coumarin dosing. 
Due to its simplicity our proposed algorithm can easily be used as a paper-based 
decision support tool. It could further be integrated in a computer program or as a 
hand-held version. Similar programs are available for warfarin on 
www.warfarindosing.org. [10] In hospitals the most efficient mode would be to 
integrate the algorithm into the electronic patient record because relevant covariates 
as gender, age, weight, comedication and laboratory values could automatically be 
included and transformed to an electronic prescription.  
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